Utopia SIS invests 1.5 million euros in DDC

Drug Discovery & Clinic S.r.l. (DDC), a spin-off of the University of Turin dedicated to the development of a platform for the creation of potentially effective drugs for different oncological scenarios, namely leukemia and breast cancer.

Utopia SIS, the investment company specialized in healthcare and biomedicine, promoted and participated by Fondazione Golinelli, Fondazione Sardegna, and Executive Vice President Antonio Falcone, has invested 1.5 million euros in Drug Discovery & Clinic S.r.l. (DDC), a spin-off of the University of Turin, to support the development of a technological platform aimed at developing treatments for leukemia and breast carcinomas.

At the core of DDC’s research team are Prof. Giuseppe Saglio, Hematologist at Mauriziano Hospital, and Prof. Giovanni Martinelli, Hematologist at the IRCCS of the Emilia Romagna Region.

In this operation as well, Utopia SIS and the Medio Credito Centrale confirm their commitment, with MCC providing an 80% guarantee on the investment.

“This fifth investment by Utopia is very important to us and is of great satisfaction because we are contributing to the support and development of a highly interesting and scientifically impactful multifunctional research. Our country is rich in clinical excellences and research hubs that need to be funded to complete the development path, and the significant commitment of the Medio Credito Centrale, also on this occasion, represents a strategic testimony for the sector,” commented Antonio Falcone, Executive Vice President of Utopia SIS.

“Molecularly targeted therapies, aimed at directly targeting the neoplastic cells that cause tumor onset, are the fundamental pillars of the most modern and effective anti-tumor therapies, often able to completely replace the more traditional and toxic chemotherapy. DDC’s mission is focused on developing new drugs of this type and evaluating their effectiveness not only in oncology but also in other medical sectors such as immunological diseases or those caused by viruses. The entry of a partner like Utopia, an investor with extensive and specific experience in healthcare, represents a very important step for the company and a source of great opportunity,” concluded Prof. Giuseppe Saglio, President and Clinical Scientific Officer of DDC.

In this operation, Utopia SIS was assisted by lawyer Chiara Izis of Studio Lener as legal advisor for the operation, and Giordano Calzoni acted as financial advisor for managing the guarantee with MCC.